Glucagon nasal powder: A promising alternative to intramuscular glucagon in youth with type 1 diabetes

Diabetes Care

Volumn 39, Issue 4, 2016, Pages 555-562

  Sherr, Jennifer L ^a   Ruedy, Katrina J ^b   Foster, Nicole C ^b   Piché, Claude A ^c   Dulude, Hélène ^c   Rickels, Michael R ^d   Tamborlane, William V ^a   Bethin, Kathleen E ^e   DiMeglio, Linda A ^f   Fox, Larry A ^g   Wadwa, R Paul ^h   Schatz, Desmond A ⁱ   Nathan, Brandon M ^j   Marcovina, Santica M ^k   Rampakakis, Emmanouil ^l   Meng, Linyan ^l   Beck, Roy W ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JAEB CENTER FOR HEALTH RESEARCH   (United States)

^c Locemia Solutions ULC   (Canada)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NEMOURS CHILDREN S CLINIC   (United States)

^h UNIVERSITY OF COLORADO DENVER   (United States)

ⁱ UNIVERSITY OF FLORIDA   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k Northwest Lipid Metabolism and Diabetes Research Laboratories   (United States)

^l JSS Medical Research   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE BLOOD LEVEL; INSULIN; POWDER;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRY POWDER; FACE DISORDER; FEMALE; GLUCOSE BLOOD LEVEL; HEAD INJURY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOMITING; BLOOD; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 1; DOSE RESPONSE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; METABOLISM; POWDER;

ADMINISTRATION, INTRANASAL; ADOLESCENT; BLOOD GLUCOSE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; INJECTIONS, INTRAMUSCULAR; INSULIN; MALE; NAUSEA; POWDERS;

EID: 84962081607     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-1606     Document Type: Article

References (25)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr 1994; 125:177-188
3. Campbell MS, Schatz DA, Chen V, et al.; T1D Exchange Clinic Network. A contrast between children and adolescents with excellent and poor control: the T1D Exchange clinic registry experience. Pediatr Diabetes 2014;15:110-117
4. Clarke WL, Gonder-Frederick A, Snyder AL, Cox DJ. Maternal fear of hypoglycemia in their children with insulin dependent diabetes mellitus. J Pediatr Endocrinol Metab 1998; 11(Suppl. 1):189-194
5. Patton SR, Dolan LM, Henry R, Powers SW. Parental fear of hypoglycemia: young children treated with continuous subcutaneous insulin infusion. Pediatr Diabetes 2007;8:362-368
6. Tsalikian E, Fox L, Weinzimer S, et al.; Diabetes Research in Children Network Study Group. Feasibility of prolonged continuous glucose monitoring in toddlers with type 1 diabetes. Pediatr Diabetes 2012;13:301-307
7. Mauras N, Beck R, Xing D, et al.; Diabetes Research in Children Network (DirecNet) Study Group. A randomized clinical trial to assess the efficacy and safety of real-time continuous glucose monitoring in the management of type 1 diabetes in young children aged 4 to ,10 years. Diabetes Care 2012;35:204-210
8. Pedersen JS. The nature of amyloid-like glu-cagon fibrils. J Diabetes Sci Technol 2010;4:1357-1367
9. Pontiroli AE,Alberetto M, Pozza G. Intranasal glucagon raises blood glucose concentrations in healthy volunteers. Br Med J (Clin Res Ed) 1983; 287:462-463
10. Pontiroli AE, Calderara A, Pajetta E, Alberetto M, Pozza G. Intranasal glucagon as remedy for hypoglycemia. Studies in healthy subjects and type I diabetic patients. Diabetes Care 1989;12:604-608
11. Freychet L, Rizkalla SW, Desplanque N, et al. Effect of intranasal glucagon on blood glucose levels in healthy subjects and hypoglycaemic patients with insulin-dependent diabetes. Lancet 1988;1:1364-1366
12. Slama G, Reach G, Cahane M, Quetin C, Villanove-Robin F. Intranasal glucagon in the treatment of hypoglycaemic attacks in children: experience at a summer camp. Diabetologia 1992;35:398
13. Hvidberg A, Djurup R, Hilsted J. Glucose recovery after intranasal glucagon during hypo-glycaemia in man. Eur J Clin Pharmacol 1994; 46:15-17
14. Boido A, Ceriani V, Pontiroli AE. Glucagon for hypoglycemic episodes in insulin-treated diabetic patients: a systematic review and meta-analysis with a comparison of glucagon with dextrose and of different glucagon formulations. Acta Diabetol 2015;52:405-412
15. Rosenfalck AM, Bendtson I, Jørgensen S, Binder C. Nasal glucagon in the treatment of hypoglycaemia in type 1 (insulin-dependent) diabetic patients. Diabetes Res Clin Pract 1992;17: 43-50
16. Rickels MR, Ruedy KJ, Foster NC, et al.; T1D Exchange Intranasal Glucagon Investigators. Intranasal glucagon for treatment of insulin induced hypoglycemia in adults with type 1 diabetes: a randomized, cross-over non-inferiority study. Diabetes Care 2016;39: 264-270
17. Beck RW, Tamborlane WV, Bergenstal RM, Miller KM, DuBose SN, Hall CA; T1D Exchange Clinic Network. The T1D Exchange clinic registry. J Clin Endocrinol Metab 2012;97:4383-4389
18. Novo Nordisk. GlucaGen prescribing information [Internet], 2014. Available from http:// www.novonordiskmedicalinformation.com//file- upload/GlucaGen%20HypoKit%20Prescribing% 20Information,April%202014%20.pdf. Accessed 16 December 2015
19. Locemia Solutions ULC. Safety and efficacy of a novel glucagon formulation in type 1 diabetic patients following insulin-induced hypoglyce-mia (AMG102) [Internet], 2014. Available from https://clinicaltrials.gov/ct2/show/NCT01556594? term=amg+medical&rank=1. Accessed 16 December 2015
20. Tsalikian E, Tamborlane W, Xing D, et al.; Diabetes ResearchinChildren Network (DirecNet) Study Group. Blunted counterregulatory hormone responses to hypoglycemia in young children and adolescents with well-controlled type 1 diabetes. Diabetes Care 2009;32:1954-1959
21. Lily. Glucagon for injection prescribing information [Internet], 2015. Available from http://pi.lilly.com/us/rglucagon-pi.pdf. Accessed 16 December 2015
22. Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration-underevaluated and undertaught. Pract Diabetes Int 2001;18: 22-25
23. Yale JF, Piche C, Lafontaine M, et al. Needle-free nasal delivery of glucagon is superior to injectable delivery in simulated hypoglycae-mia rescue [Internet], 2015. Available from http://www.easdvirtualmeeting.org/resources/ needle-free-nasal-delivery-of-glucagon-is-superior-to-injectable-delivery-in-simulated-hypoglycaemia-rescue-3. Accessed 16 December 2015
24. Glu. Frequency of carrying glucagon [Internet], 2015. Available from https://myglu.org/polls/ 1303. Accessed 16 December 2015
25. Driscoll KA, Volkening LK, Haro H, et al. Are children with type 1 diabetes safe at school? Examining parent perceptions. Pediatr Diabetes 2015;16:613-620